CVRS CORINDUS VASCULAR ROBOTICS

Corindus to Report First Quarter 2019 Financial Results on May 7, 2019

WALTHAM, Mass.--(BUSINESS WIRE)--

Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it will release first quarter 2019 financial and business results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.

Mark Toland, President and Chief Executive Officer, and David Long, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date   Tuesday, May 7, 2019
Time

4:30 p.m. EDT

Toll free (U.S.) (833) 286-5802
International (647) 689-4447
Conference ID: 5649418
Webcast (live and replay)

under the ‘Investor Relations’ section.

About Corindus Vascular Robotics, Inc.

is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit , and follow @CorindusInc.

EN
29/04/2019

Underlying

CVRSCORINDUS VASCULAR ROBOTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CORINDUS VASCULAR ROBOTICS

 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

Corindus Vascular Robotics, Inc. Stockholders Approve Acquisition by S...

WALTHAM, Mass.--(BUSINESS WIRE)-- At a special meeting today, stockholders of Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS) approved the adoption of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 7, 2019, by and among Siemens Medical Solutions USA, Inc. (“SMS USA”), Corpus Merger Inc. (“Merger Sub”) and Corindus. Subject to the terms and conditions of the Merger Agreement, Merger Sub, a wholly owned subsidiary of SMS USA, will be merged with and into Corindus, with Corindus surviving the merger as a wholly owned subsidiary o...

October 25, 2019 1 EN
 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

Corindus to Showcase CorPath® GRX System at Transcatheter Cardiovascu...

WALTHAM, Mass.,--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it will showcase the capabilities of the CorPath® GRX system at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 Conference, to be held September 25-29 in San Francisco, California. CorPath GRX is the only U.S. Food and Drug Administration (“FDA”) cleared and CE-marked medical device for robotic-assisted vascular interventions. At Corindus’ booth 1327, attendees will be able to gain hands-on experience with CorPath GRX in an advanc...

September 18, 2019 1 EN
 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

First-in-Human Telerobotic Coronary Intervention Procedures Published ...

WALTHAM, Mass.--(BUSINESS WIRE)-- (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that EClinicalMedicine, a clinical journal published by the nearly 200-year-old medical journal The Lancet, has published the results from the , the world’s first percutaneous coronary intervention (PCI) procedures conducted from a remote location outside the catheterization lab using Corindus’ CorPath technology platform. The paper, titled Long Distance Telerobotic-Assisted Percutaneous Coronary Intervention: First-in-Human Experience, d...

September 3, 2019 1 EN
 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

Corindus Reports Second Quarter 2019 Results

WALTHAM, Mass.--(BUSINESS WIRE)-- , Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its second quarter ended June 30, 2019. Corindus also announced today that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggr...

August 8, 2019 1 EN
 PRESS RELEASE
Free
CVRS CORINDUS VASCUL...

Corindus Vascular Robotics Announces Definitive Agreement to Be Acquir...

WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion. “We are pleased to ...

August 8, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch